PGEN News and Press, Precigen Inc.

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years PR Newswire 15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months with...

Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States PR Newswire FDA grants orphan drug exclusivity for PAPZIMEOS for the treatment of adults with recurrent respiratory papillomatosis Seven-year period of PAPZIMEOS market exc...

Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference PR Newswire GERMANTOWN, Md. , May 26, 2026 /PRNewswire/ -- Precigen, Inc.  (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing ...

2026-05-21 16:52:47 ET Precigen, Inc.’s ( PGEN ) launch of Papzimeos in recurrent respiratory papillomatosis ((RRP)) continues. My last analysis was in March and followed the company's fourth-quarter earnings , in which management detailed interim Q1 revenue. Q1 was P...

2026-05-14 13:53:50 ET More on Precigen Precigen: Full Commercial Validation And Room To Run Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP Transcript ...

2026-05-14 09:58:11 ET Since my first BUY report on Precigen ( PGEN ) last summer, the stock is up 156%. Priced at $1.62 and facing an FDA approval decision in August, I argued that an investment was warranted because: PRGN-2012 showed remarkable efficacy and safety, and ...

2026-05-14 07:15:05 ET H.C. Wainwright analyst issues BUY recommendation for PGEN on May 14, 2026 10:09AM ET. The previous analyst recommendation was Buy. PGEN was trading at $4.15 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...

2026-05-13 22:41:38 ET More on Precigen Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP Transcript Precigen: The Best Potential Blockbuster You've Never Heard O...

2026-05-13 22:40:49 ET Precigen, Inc. (PGEN) Q1 2026 Earnings Call May 13, 2026 4:30 PM EDT Company Participants Steven Harasym - VP & Head of Investor Relations Helen Sabzevari - President, CEO & Director Phil Tennant - Chief Commercial Officer Harry...

2026-05-13 17:47:01 ET Image source: The Motley Fool. Wednesday, May 13, 2026 at 4:30 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading